KR102056511B1 - mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법 - Google Patents

mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법 Download PDF

Info

Publication number
KR102056511B1
KR102056511B1 KR1020157021685A KR20157021685A KR102056511B1 KR 102056511 B1 KR102056511 B1 KR 102056511B1 KR 1020157021685 A KR1020157021685 A KR 1020157021685A KR 20157021685 A KR20157021685 A KR 20157021685A KR 102056511 B1 KR102056511 B1 KR 102056511B1
Authority
KR
South Korea
Prior art keywords
cells
mrna
cell
protein
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157021685A
Other languages
English (en)
Korean (ko)
Other versions
KR20160031999A (ko
Inventor
마크 씨 허즈버그
카렌 파니 로스
브렌트 에스 소렌슨
Original Assignee
마크 씨 허즈버그
카렌 파니 로스
브렌트 에스 소렌슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크 씨 허즈버그, 카렌 파니 로스, 브렌트 에스 소렌슨 filed Critical 마크 씨 허즈버그
Publication of KR20160031999A publication Critical patent/KR20160031999A/ko
Application granted granted Critical
Publication of KR102056511B1 publication Critical patent/KR102056511B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157021685A 2013-01-11 2014-01-10 mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법 Active KR102056511B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
US61/751,504 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187006399A Division KR102119985B1 (ko) 2013-01-11 2014-01-10 mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20160031999A KR20160031999A (ko) 2016-03-23
KR102056511B1 true KR102056511B1 (ko) 2019-12-16

Family

ID=51167392

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157021685A Active KR102056511B1 (ko) 2013-01-11 2014-01-10 mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법
KR1020187006399A Active KR102119985B1 (ko) 2013-01-11 2014-01-10 mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187006399A Active KR102119985B1 (ko) 2013-01-11 2014-01-10 mRNA 트랜스펙션을 수반하는 치료 조성물 및 방법

Country Status (13)

Country Link
US (3) US20150344537A1 (cg-RX-API-DMAC10.html)
EP (2) EP2943226B1 (cg-RX-API-DMAC10.html)
JP (4) JP2016511230A (cg-RX-API-DMAC10.html)
KR (2) KR102056511B1 (cg-RX-API-DMAC10.html)
CN (1) CN105473163A (cg-RX-API-DMAC10.html)
AU (1) AU2014205298B2 (cg-RX-API-DMAC10.html)
CA (2) CA2901409C (cg-RX-API-DMAC10.html)
ES (1) ES2738315T3 (cg-RX-API-DMAC10.html)
IL (2) IL239898B (cg-RX-API-DMAC10.html)
NZ (1) NZ710495A (cg-RX-API-DMAC10.html)
PL (1) PL2943226T3 (cg-RX-API-DMAC10.html)
SG (2) SG10201603946PA (cg-RX-API-DMAC10.html)
WO (1) WO2014110366A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7754676B2 (en) * 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
WO2004089292A2 (en) * 2003-04-04 2004-10-21 The Regents Of The University Of California Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
CA2831613A1 (en) * 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Khammanivong, Ali. University of Minnesota. (2011.07. 공개)*
Thierry Bettinger et al. Nucleic acids research, Vol. 29(18), pages 3882-3891 (2001년 공개)*

Also Published As

Publication number Publication date
IL239898A0 (en) 2015-08-31
WO2014110366A1 (en) 2014-07-17
EP2943226B1 (en) 2019-03-13
PL2943226T3 (pl) 2019-09-30
SG11201505431XA (en) 2015-08-28
EP3501551C0 (en) 2023-06-07
US11912744B2 (en) 2024-02-27
EP2943226A4 (en) 2016-11-23
IL262252B (en) 2020-06-30
JP6473729B2 (ja) 2019-02-20
CN105473163A (zh) 2016-04-06
US20240166701A1 (en) 2024-05-23
US12448421B2 (en) 2025-10-21
US20200231640A1 (en) 2020-07-23
EP3501551B1 (en) 2023-06-07
JP2017052781A (ja) 2017-03-16
EP3501551A1 (en) 2019-06-26
KR20180026811A (ko) 2018-03-13
CA3152721C (en) 2025-11-18
ES2738315T3 (es) 2020-01-21
KR20160031999A (ko) 2016-03-23
JP2016511230A (ja) 2016-04-14
AU2014205298B2 (en) 2018-11-01
IL239898B (en) 2018-10-31
JP2019031521A (ja) 2019-02-28
EP2943226A1 (en) 2015-11-18
CA3152721A1 (en) 2014-07-17
KR102119985B1 (ko) 2020-06-05
CA2901409C (en) 2022-06-07
AU2014205298A1 (en) 2015-08-13
JP6956059B2 (ja) 2021-10-27
NZ710495A (en) 2019-10-25
US20150344537A1 (en) 2015-12-03
CA2901409A1 (en) 2014-07-17
IL262252A (en) 2018-11-29
JP2021019644A (ja) 2021-02-18
SG10201603946PA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US12448421B2 (en) Non-transgene transfection for therapeutic purposes
CN114606323B (zh) 一种识别胃癌干细胞的标志物lgsn作为胃癌诊断和治疗靶标的应用
CN105358173A (zh) 靶向癌症治疗的egfr-sglt1相互作用
JP5762103B2 (ja) 頭頸部癌及び食道癌用抗癌剤及び増強剤
CN111686248A (zh) 一种治疗癌症的药物
WO2024230090A1 (zh) 唾液酸转移酶抑制剂在制备中和酸性肿瘤微环境的药物中应用
RU2718499C2 (ru) Способы и композиции для предупреждения или лечения злокачественной опухоли
Alsanani et al. Stromal carcinoma associated fibroblasts promote drug resistance of human pancreatic cancer cells by modulation of ROS via CXCR4/CXCL12 signaling
US9885044B2 (en) Polynucleotides and methods for inhibiting cancer cells
WO2024064879A2 (en) Interferon lambda (ifnl) inhibition in intestinal epithelial cells for treating inflammation
KR101848106B1 (ko) Gkn2를 유효성분으로 포함하는 항암 보조제
JP2012012330A (ja) 癌転移抑制剤及び医薬組成物

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20150811

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160822

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20170330

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171026

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170330

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20160822

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20171026

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170530

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20161122

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150811

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180201

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171222

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20171026

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170530

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20170330

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161122

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160822

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150811

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180305

PJ0201 Trial against decision of rejection

Patent event date: 20180305

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180201

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20171026

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20191017

Appeal identifier: 2018101001007

Request date: 20180305

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101001007; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180305

Effective date: 20191017

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20191017

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180305

Decision date: 20191017

Appeal identifier: 2018101001007

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20191028

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20191022

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191210

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20221214

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20221214

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241126

Start annual number: 6

End annual number: 6